Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
December 9, 2019

Bristol-Myers Squibb’s Liso-Cel meets key endpoints in blood cancer trial

Bristol-Myers Squibb announced that its blood cancer treatment lisocabtagene maraleucel (liso-cel) has achieved its primary and secondary endpoints in TRANSCEND NHL 001 study.

Image: Bristol-Myers Squibb’s blood cancer treatment Liso-Cel has achieved primary and secondary endpoints in TRANSCEND NHL 001 study. Photo: courtesy of Rept0n1x.